




Average LDL-C lowering effect of different lipid-lowering treatments



Lipid-lowering therapies

- Moderate-intensity statin
- High-intensity statin
- Ezetimibe
- Bempedoic acid
- Ezetimibe + Bempedoic acid
- High-intensity statin + Ezetimibe
- High-intensity statin + Bempedoic acid
- High-intensity statin + Ezetimibe + Bempedoic acid
- PCSK9 mAb
- PCSK9 mAb + Ezetimibe
- PCSK9 mAb + Ezetimibe + Bempedoic acid
- High-intensity statin + PCSK9 mAb
- High-intensity statin + Ezetimibe + PCSK9 mAb
- High-intensity statin + Ezetimibe + Bempedoic acid + PCSK9 mAb

All the lipid-lowering treatments featured within this graph have proven cardiovascular benefits

Adapted from: Mach F, et al. Eur Heart J. 2025.¹

Inclisiran can reduce LDL-C levels by ~50%²

LDL-C, low-density lipoprotein cholesterol; PCSK9 mAb, proprotein convertase subtilisin/kexin type 9 monoclonal antibody.

1. Mach F, et al. Eur Heart J. 2025;00:1–20; 2. Albosta MS, et al. Vasc Health Risk Manag. 2023;19:421–431.

This programme has been organised by PCCS and funded by Novartis. Novartis were not involved in the development of the programme, content, selection of speakers or their arrangements. All content has been independently developed by PCCS.